This article is sponsored by Yes Clinic.
Bought a vial of BPC-157 or TB-500 lately? Then this one’s for you. A draft federal policy published on October 30 opens a prescription route for six named peptides, BPC-157 and TB-500 among them, and leaves CJC-1295, Ipamorelin, GHK-Cu and every blend outside it.
If you buy by the vial, check your last order against the list. The policy’s own appendix has six names: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. No other peptide is covered, and no blend of any kind.
Here’s the part that should make you look twice. FDA keeps a public page of compounding ingredients that “may present significant safety risks”. Its Ipamorelin entry cites a published study that found “serious adverse events including death” when ipamorelin was given intravenously to improve gastric motility. Its CJC-1295 entry cites “serious adverse events associated with CJC-1295”. Neither peptide made the list.
Let’s break down what’s on the list, what’s off it, what it means for the research vial in your fridge, and how the prescription route works.
Key takeaways
- The draft HHS policy names six peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax, each with a fixed form and route. 📋
- CJC-1295, Ipamorelin, GHK-Cu and every blend are left off. FDA’s safety page cites “serious adverse events including death” for Ipamorelin. 🚩
- The policy doesn’t cover research vials, whatever the label says. 🧪
- It’s a draft. It “is not binding”, and HHS can withdraw it. ⚖️
- Four of the six can be prescribed through Yes Clinic, from $149 a vial. Compounded medications are not FDA-approved. 💵
Is the HHS Policy Final?
None of it is settled. The notice in the Federal Register says the policy “does not establish any rights for any person and is not binding”. Public comment closed at 11:59 pm Eastern on November 13. As of November 20, the docket shows 115 posted comments, none posted since November 6, so letters filed near the deadline are not visible yet. HHS has not finalized, changed or withdrawn the draft.
The promise itself is narrow. “HHS does not intend to take enforcement action against a State-licensed pharmacy” that compounds a listed peptide, the notice says, and the policy lists ten conditions a pharmacy has to meet first.
Which Peptides Are on the HHS Peptide List?
The policy fixes a form and a route for each peptide, and a match on identity and route is among the ten conditions. The last column quotes FDA’s safety risks page.
| Peptide | Form named | Routes covered | FDA’s earlier words |
|---|---|---|---|
| BPC-157 | Acetate | Subcutaneous, intramuscular, oral, topical | “may pose risk for immunogenicity for certain routes of administration” |
| TB-500 | Acetate | Subcutaneous or intramuscular injection | “potential for aggregation as well as peptide-related impurities” |
| Epitalon | Acetate | Subcutaneous or intramuscular injection, “dispensed in intermittent courses” | “potential for aggregation and peptide-related impurities” |
| KPV | Acetate | Topical and oral | FDA had “not identified any human exposure data” |
| MOTS-c | Acetate | Subcutaneous or intramuscular injection | “lacks important information regarding any safety issues raised” |
| Semax | Free base | Intranasal only | “no, or limited, safety-related information” |
Routes: HHS policy, Appendix B. FDA quotes: “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks”, current as of April 22, 2026.
Semax is covered only as a nasal product. KPV is covered on the skin and by mouth. It is not covered as an injection.
BPC-157 gets the widest reach, with four routes. The oral one has a catch: for any oral peptide, oral KPV included, the policy expects the pharmacy to keep documentation that the formulation “achieves an adequate level of oral bioavailability in humans”.
Are Peptide Blends Covered?
No. Condition seven in the policy: a single active ingredient only.
A blend has at least two. That holds even when both halves are on the list, BPC-157 with TB-500 for one, and on that wording the vial is outside. LegitScript, the private company that certifies online health sellers, reads the policy the same way: other peptides and combinations stay outside.
The device rule is as tight. The only one the policy allows is a syringe with FDA 510(k) clearance, and LegitScript warns that businesses “should not assume that clearance of a different device, such as an injector pen, satisfies this requirement”.
Which Peptides Were Left Off?
The policy does not ban these peptides. It leaves them off, so a pharmacy compounding them gets no cover.
| Not on the list | FDA’s own words |
|---|---|
| Ipamorelin | “serious adverse events including death” |
| CJC-1295 | “serious adverse events associated with CJC-1295” |
| Thymosin alpha-1 | “safety-related information is inadequate” |
| AOD-9604, GHK-Cu (injectable), Melanotan II, DSIP, Selank, LL-37, Dihexa | Each is on the same FDA page, among substances withdrawn from its safety category by the people who nominated them |
Source: FDA, same page, current as of April 22, 2026.
One detail matters here. On April 22, 2026, all of these except Ipamorelin, along with the six on the HHS list, were withdrawn by their nominators from FDA’s Category 2, the group it flags for safety risks. FDA’s notes on them stay on the page. Ipamorelin is still in Category 2 for outsourcing facilities (503B). FDA’s Ipamorelin note comes from a published study in which ipamorelin was given intravenously for gastric motility.
GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF are due at an advisory committee before the end of February 2027, according to Holland & Knight. As of November 20, FDA had not set a date.
Does the Policy Cover Your Research Vial?
No. A listed name does not carry over to a vial sold for research. The policy does not cover “products sold as research chemicals or dietary supplements”, BakerHostetler wrote. HHS wrote that the policy “will discourage the continued, widespread use of certain research-use-only peptides”, in a passage quoted by RAPS.
You read certificates of analysis. A research seller’s certificate is a PDF the seller chose to send you. A pharmacy’s is required by federal law. Under 21 U.S.C. 353a, the bulk ingredient must be “manufactured by an establishment that is registered” with FDA and “accompanied by valid certificates of analysis”. The drug must be “compounded for an identified individual patient” on “a valid prescription order”, by “a licensed pharmacist in a State licensed pharmacy or a Federal facility”.
State boards of pharmacy hold “primary responsibility for the day-to-day oversight”, FDA says. No part of 353a applies to a vial sold “for research use only”, and FDA treats such products as unapproved new drugs when they are meant for people.
A preprint posted in April 2026 by Mendias and Awan, not peer reviewed, analyzed 6,441 samples of 14 research-grade peptides, BPC-157 and TB-500 among them, all sent in voluntarily. It reported that 41.6% failed a lenient standard and 71.1% failed a strict one, with endotoxin detectable in 15% of the subset tested for it. Voluntary samples are not a random draw from the market, and we found no other lab study of grey-market vials of these six.
Pharmacies get it wrong too. In 2026 the CDC reported more than 25 people sick in at least four states after glutathione injections, at least three of them hospitalized, “likely linked to elevated levels of endotoxins”. FDA said on August 27 that the glutathione had been compounded by different compounding pharmacies, using an ingredient labeled dietary supplement grade.
What Do Critics Say, and How Could the Draft End?
“All peptide substances should go through the standard FDA approval process for new drugs,” said Robert Steinbrook of Public Citizen’s Health Research Group, in remarks reported by RAPS. Public Citizen filed formal comments on November 13 urging HHS to reconsider.
Doctors have joined in since the comment period closed. On November 18 the American Medical Association asked HHS to rescind what it called a “rushed” decision. “We should not bypass the science and put patients at risk by making them guinea pigs for unapproved drugs,” said AMA President Willie Underwood III.
The notice went out over the signature of Robert F. Kennedy Jr., from the HHS Office of the Secretary rather than from FDA. FDA “scientific staffers had little input on the decision and opposed the changes”, the Associated Press reported.
The margin was thin. An FDA advisory committee backed six of seven peptides in July, and BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention, according to Holland & Knight. FDA’s drug center had recommended against listing. The Partnership for Safe Medicines filed a citizen petition against the compounding in October.
The exits are written into the draft. HHS “may revisit application of this interim policy (in whole or in part)” if “a safety signal or product quality issue arises”, the notice says. Arnold & Porter says it “can be withdrawn without notice and comment”. It “does not displace applicable state laws”, according to Holland & Knight. A Federation of State Medical Boards FAQ says the same: the policy “does not itself amend federal statutory requirements, state law, or state board authority”. Medical boards in Alabama, Mississippi and South Carolina have already issued notices on research-grade peptides.
The six are still not on FDA’s 503A bulks list. “FDA’s future rulemakings may propose adding some or all of these peptides,” the notice says. It also says: “Compounded drugs are not FDA-approved.”
How Does the Prescription Route Work at Yes Clinic?
Four of the six can be prescribed through Yes Clinic, a telehealth clinic: BPC-157, TB-500 and MOTS-c as injections, and Semax as a nasal spray. Each is a single ingredient, in a form and route the list names.
What separates this from a research vial is the paperwork described above. Any prescription is written in your name and filled by a licensed U.S. pharmacy. Compounded medications are not FDA-approved; FDA does not review them for safety, effectiveness or quality.
- Choose a plan and pay on the secure checkout.
- Answer the health questions online, straight after.
- A licensed U.S. provider reads your answers and decides whether to prescribe. There is no promise of a prescription.
- If one is written, a licensed U.S. pharmacy fills it in your name and ships it cold and pre-mixed.
| Product | Form | One | Three | Six |
|---|---|---|---|---|
| BPC-157 | Injection | $149 | $399 | $749 |
| TB-500 | Injection | $149 | $399 | $749 |
| MOTS-c | Injection | $179 | $499 | $929 |
| Semax | Nasal spray | $159 | $439 | $829 |
Injections are priced per vial, Semax per bottle. Provider review, medication and shipping are included, with no processing fee and no membership. If the provider turns you down at first review, you get your payment back in full. First-time patients can start with one BPC-157 vial at $99 using code FIRST50 (1 vial plan, if prescribed). Not available in Alabama or Ohio.
The limits. The policy behind this route is a draft and can be withdrawn. A provider may say no. State law still applies, so availability can vary by state. A licensed pharmacy answers to a state board, and the glutathione cases show that oversight can still fail. Nobody here can tell you what a peptide will do for you.
Start with a $99 first vial of BPC-157 →
Conclusion
The HHS list is short: six single peptides, each with a fixed form and route. CJC-1295, Ipamorelin, GHK-Cu and every blend are off it, and so is any vial sold for research. The policy is a draft, it binds nobody, and HHS can pull it. If you want one of the listed peptides with a pharmacy and a prescription behind it, that route now exists, but a provider decides, and compounded medications are not FDA-approved.
For more, see SarmGuide’s peptide section.
See the peptides on prescription at Yes Clinic →
Important safety information. Yes Clinic is a telehealth clinic and not a pharmacy. It does not make or compound medication, and a licensed U.S. pharmacy fills your prescription. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness or quality. A provider writes a prescription only when they judge it appropriate, and availability varies by state. The HHS policy in this article is a draft; it is not binding and HHS can withdraw it. HHS, FDA, the CDC, Public Citizen, the Associated Press, RAPS, Healio, LegitScript, the law firms and the researchers named in this article have no connection to Yes Clinic and do not endorse it.
DISCLAIMER: The information provided above is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek your physician’s advice or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have seen or read.We bear no responsibility or liability for your use of any compound.
Frequently asked questions
Which peptides are on the HHS peptide list?
Six, according to the draft policy's appendix: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. Each has a named form and route. Semax is intranasal only, and KPV is topical and oral.
Are CJC-1295 and Ipamorelin covered?
No. Neither is on the list. FDA's safety risks page cites "serious adverse events associated with CJC-1295" and, for Ipamorelin, a published study that found "serious adverse events including death" when it was given intravenously.
Are peptide blends covered?
No. One of the policy's ten conditions is a single active ingredient only, and LegitScript reads combinations as outside the policy.
Is BPC-157 FDA-approved now?
No. The notice itself says "Compounded drugs are not FDA-approved". Compounded medications are not FDA-approved; FDA does not review them for safety, effectiveness or quality. The policy is a draft about enforcement, and it is not binding.
Does the policy cover research peptides?
No. BakerHostetler reads it as leaving out "products sold as research chemicals or dietary supplements".
When did the comment period close?
At 11:59 pm Eastern on November 13, 2026. The docket, HHS-OASH-2026-0496, is on regulations.gov. As of November 20, HHS had not finalized, changed or withdrawn the draft.